Curatis Passes Technical Evaluation... "Tuberculosis and COVID-19 Vaccine Clinical Trials Progressing Smoothly"

Curatis Osong Bio Plant.

[Asia Economy Reporter Lee Gwan-joo] Curatis announced on the 24th that it has passed the technical evaluation conducted by eCredible and NICE Credit Information, both designated technical evaluation institutions by the Korea Exchange.

The technical evaluation is the first hurdle for KOSDAQ technology special listing, a system that selects promising technology companies with outstanding technological capabilities. This year, the criteria for technical evaluation for technology special listing were strictly revised, with evaluation items subdivided into 35 categories, further strengthening the objective verification of technology and business feasibility.

With the completion of this technical evaluation, Curatis plans to file a preliminary listing review as soon as possible and enter an initial public offering (IPO) for KOSDAQ listing within this year.

Founded in 2016, Curatis is a global vaccine specialist company, recognized as the frontrunner in commercializing the adult and adolescent tuberculosis vaccine QTP101. Recently, it recruited Kim Cheon-tae, director of the Tuberculosis Research Institute, as a full-time expert advisor to accelerate the development and commercialization of the tuberculosis vaccine.

Additionally, for the next-generation mRNA COVID-19 vaccine QTP104, clinical phase 1 trials were approved by the Ministry of Food and Drug Safety in July last year and are being conducted at Sinchon and Gangnam Severance Hospitals. The vaccine administration is expected to be completed within the first half of this year, with the goal of concluding clinical trials in the second half. Booster shot clinical trials are also planned to be conducted simultaneously within the first half of this year.

Furthermore, Curatis obtained GMP (Good Manufacturing Practice) certification for its production facility, Osong Bio Plant, in January. With the launch of the vitamin C injection 'Cuac C Injection (Ascorbic Acid)', the commercial production operation of Osong Bio Plant has officially started, accelerating preparations for the commercialization of the main development products QTP101 and QTP104.

A Curatis official stated, "Passing this technical evaluation has proven the company's excellent vaccine development platform technology, and by recruiting tuberculosis expert Kim Cheon-tae as an expert advisor, we have further solidified our expertise in the tuberculosis vaccine research field. Through the upcoming KOSDAQ listing, we plan to establish a stable financial structure and accelerate growth as a global vaccine specialist company through continuous research and development activities."

This content was produced with the assistance of AI translation services.